Joel Blanchard, Braxton Schuldt on Does a Rare Fibronectin Variant Protect Against APOE4?

COMMENT APOE4 is the strongest risk factor for Alzheimer’s disease. APOE4 homozygosity was recently identified as a distinct, highly penetrant form of AD. However, a small percentage of APOE4 homozygotes live cognitively normal lives into their 80s and beyond (Fo

Does a Rare Fibronectin Variant Protect Against APOE4?

RESEARCH NEWS 2024-05-16 Research News APOE4 strongly increases the risk of sporadic Alzheimer’s disease. Yet some carriers evade the disease entirely. Now, scientists led by Richard Mayeux, Caghan Kizil, and Badri Vardarajan of Columbia University in New York peg some of that pr

PAPER Thornton P, Reader V, Digby Z, Smolak P, Lindsay N, Harrison D, Clarke N, Watt AP

Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796.

J Pharmacol Exp Ther. 2024 Feb 15;388(3):813-826. PubMed.

PAPER Smolak P, Nguyen M, Diamond C, Wescott H, Doedens JR, Schooley K, Snouwaert JN, Bock MG, Harrison D, Watt AP, Koller BH, Gabel CA

Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances Potency.

J Pharmacol Exp Ther. 2024 Feb 15;388(3):798-812. PubMed.

Steven Sweeney

Aliada Therapeutics
Boston, United States

PAPER Athauda D, Gulyani S, Karnati HK, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.

JAMA Neurol. 2019 Apr 1;76(4):420-429. PubMed.

Jean Philippe Plichta

France

Xianbo Zhou

AstraNeura
Pudong, China

Kathleen Haaland

University of New Mexico School of Medicine
Albuquerque, United States

PAPER Rahman MS, Harrison E, Biggs H, Seikus C, Elliott P, Breen G, Kingston N, Bradley JR, Hill SM, Tom BD, Chinnery PF

Dynamics of cognitive variability with age and its genetic underpinning in NIHR BioResource Genes and Cognition cohort participants.

Nat Med. 2024 May 14; PubMed.

Steve Lenio

Boston University
United States

AD/PD™ 2025: Advances in Science & Therapy

CONFERENCE 2025-04-01 00:00:00-2025-04-05 00:00:00 Vienna, Austria 01 &#x2013 05 April 2025 View Conference Website 0

PAPER Svenningsson P, Wirdefeldt K, Yin L, Fang F, Markaki I, Efendic S, Ludvigsson JF

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study.

Mov Disord. 2016 Sep;31(9):1422-3. Epub 2016 Jul 19 PubMed.

PAPER Leon N, LaCoursiere R, Yarosh D, Patel RS

Lixisenatide (Adlyxin): A Once-Daily Incretin Mimetic Injection for Type-2 Diabetes.

P T. 2017 Nov;42(11):676-711. PubMed.

Peter OBrien

CARLSBAD, United States